UroGen Pharma (URGN) Stock Forecast, Price Target & Predictions
URGN Stock Forecast
UroGen Pharma stock forecast is as follows: an average price target of $25.00 (represents a 134.96% upside from URGN’s last price of $10.64) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.
URGN Price Target
The average price target for UroGen Pharma (URGN) is $25.00 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $25.00. This represents a potential 134.96% upside from URGN's last price of $10.64.
URGN Analyst Ratings
According to 9 Wall Street analysts, UroGen Pharma's rating consensus is 'Buy'. The analyst rating breakdown for URGN stock is 0 'Strong Buy' (0.00%), 7 'Buy' (77.78%), 2 'Hold' (22.22%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
UroGen Pharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 14, 2024 | Jason Kolbert | EF Hutton | $25.00 | $12.60 | 98.41% | 134.96% |
| Jun 14, 2024 | Stephen Richardson | Evercore ISI | $46.00 | $20.26 | 127.05% | 332.33% |
| Jun 14, 2024 | Leland Gershell | Oppenheimer | $40.00 | $17.50 | 128.57% | 275.94% |
| Jun 14, 2024 | Raghuram Selvaraju | H.C. Wainwright | $60.00 | $17.50 | 242.86% | 463.91% |
| Jun 14, 2024 | Paul Choi | Goldman Sachs | $22.00 | $17.50 | 25.71% | 106.77% |
| May 14, 2024 | Leland Gershell | Oppenheimer | $32.00 | $13.07 | 144.84% | 200.75% |
| Mar 15, 2024 | Leland Gershell | Oppenheimer | $34.00 | $14.46 | 135.13% | 219.55% |
| Dec 12, 2022 | H.C. Wainwright | $23.00 | $7.94 | 189.67% | 116.17% |
The latest UroGen Pharma stock forecast, released on Oct 14, 2024 by Jason Kolbert from EF Hutton, set a price target of $25.00, which represents a 98.41% increase from the stock price at the time of the forecast ($12.60), and a 134.96% increase from URGN last price ($10.64).
UroGen Pharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 7 |
| Avg Price Target | - | $25.00 | $37.00 |
| Last Closing Price | $10.64 | $10.64 | $10.64 |
| Upside/Downside | -100.00% | 134.96% | 247.74% |
In the current month, the average price target of UroGen Pharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to UroGen Pharma's last price of $10.64. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 16, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Oct 14, 2024 | EF Hutton | Buy | Initialise | |
| Oct 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 18, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 22, 2024 | Guggenheim | Buy | Initialise | |
| Aug 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 14, 2024 | Benchmark | Buy | Buy | Hold |
| Jun 14, 2024 | Keefe, Bruyette & Woods | Outperform | Upgrade | |
| Jun 14, 2024 | Stephens | Equal-Weight | Equal-Weight | Hold |
| Jun 14, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jun 14, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 14, 2024 | Goldman Sachs | Neutral | Neutral | Hold |
| Jun 13, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 14, 2024 | Oppenheimer | Outperform | Outperform | Hold |
UroGen Pharma's last stock rating was published by Oppenheimer on Oct 16, 2024. The company gave URGN a "Outperform" rating, the same as its previous rate.
UroGen Pharma Financial Forecast
UroGen Pharma Revenue Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $20.85M | $21.14M | $17.19M | $18.09M | $16.10M | $16.60M | $13.56M | $16.17M | $11.35M |
| Avg Forecast | $187.30M | $180.09M | $180.09M | $172.89M | $183.65M | $176.59M | $176.59M | $169.52M | $101.78M | $97.87M | $97.87M | $93.95M | $48.43M | $35.41M | $27.24M | $22.82M | $26.13M | $24.20M | $23.97M | $21.39M | $22.57M | $20.03M | $20.12M | $17.11M | $18.51M | $20.15M | $17.22M | $15.17M | $16.24M | $15.37M |
| High Forecast | $198.02M | $190.41M | $190.41M | $182.79M | $194.17M | $186.70M | $186.70M | $179.23M | $107.61M | $103.47M | $103.47M | $99.34M | $51.20M | $37.44M | $28.80M | $23.04M | $26.97M | $25.59M | $23.97M | $22.62M | $23.07M | $20.04M | $21.27M | $18.09M | $19.57M | $20.15M | $17.22M | $15.17M | $16.24M | $15.37M |
| Low Forecast | $180.13M | $173.20M | $173.20M | $166.28M | $176.63M | $169.83M | $169.83M | $163.04M | $97.89M | $94.13M | $94.13M | $90.36M | $46.58M | $34.05M | $26.19M | $22.60M | $25.28M | $23.28M | $23.97M | $20.57M | $22.06M | $20.03M | $19.35M | $16.46M | $17.80M | $20.15M | $17.22M | $15.17M | $16.24M | $15.37M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 1.05% | 1.00% | 0.98% | 0.80% | 0.96% | 0.89% | 1.00% | 0.74% |
UroGen Pharma's average Quarter revenue forecast for Dec 23 based on 3 analysts is $22.57M, with a low forecast of $22.06M, and a high forecast of $23.07M. URGN's average Quarter revenue forecast represents a 8.23% increase compared to the company's last Quarter revenue of $20.85M (Sep 23).
UroGen Pharma EBITDA Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-12.18M | $-15.38M | $-20.98M | $-19.88M | $-17.17M | $-18.11M | $-21.50M | $-27.97M | $-29.76M |
| Avg Forecast | $-178.74M | $-171.87M | $-171.87M | $-165.00M | $-175.27M | $-168.52M | $-168.52M | $-161.78M | $-97.14M | $-93.40M | $-93.40M | $-89.66M | $-46.22M | $-33.79M | $-25.99M | $-21.78M | $-24.94M | $-23.10M | $-22.87M | $-20.41M | $-21.54M | $-19.12M | $-19.20M | $-16.33M | $-17.67M | $-19.23M | $-16.44M | $-29.00 | $-15.50M | $-14.66M |
| High Forecast | $-171.91M | $-165.30M | $-165.30M | $-158.68M | $-168.56M | $-162.08M | $-162.08M | $-155.60M | $-93.42M | $-89.83M | $-89.83M | $-86.23M | $-44.45M | $-32.50M | $-25.00M | $-21.57M | $-24.13M | $-22.22M | $-22.87M | $-19.63M | $-21.06M | $-19.12M | $-18.47M | $-15.70M | $-16.99M | $-19.23M | $-16.44M | $-23.00 | $-15.50M | $-14.66M |
| Low Forecast | $-188.98M | $-181.72M | $-181.72M | $-174.45M | $-185.31M | $-178.18M | $-178.18M | $-171.05M | $-102.70M | $-98.75M | $-98.75M | $-94.80M | $-48.87M | $-35.73M | $-27.48M | $-21.99M | $-25.74M | $-24.42M | $-22.87M | $-21.58M | $-22.02M | $-19.12M | $-20.30M | $-17.26M | $-18.68M | $-19.23M | $-16.44M | $-35.00 | $-15.50M | $-14.66M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.64% | 0.80% | 1.28% | 1.13% | 0.89% | 1.10% | 741482.76% | 1.80% | 2.03% |
undefined analysts predict URGN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than UroGen Pharma's previous annual EBITDA (undefined) of $NaN.
UroGen Pharma Net Income Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-21.88M | $-24.14M | $-30.21M | $-28.25M | $-25.83M | $-26.69M | $-28.39M | $-28.45M | $-30.21M |
| Avg Forecast | $49.41M | $48.51M | $49.54M | $40.35M | $43.95M | $43.38M | $44.54M | $42.48M | $21.52M | $21.90M | $23.28M | $21.34M | $-19.02M | $-28.57M | $-34.32M | $-34.66M | $-30.97M | $-35.22M | $-35.86M | $-37.35M | $-29.31M | $-36.46M | $-48.96M | $-57.32M | $-46.26M | $-42.59M | $-46.95M | $-30.00 | $-43.27M | $-47.13M |
| High Forecast | $53.08M | $52.12M | $53.23M | $43.35M | $47.22M | $46.61M | $47.86M | $45.64M | $23.13M | $23.53M | $25.02M | $22.93M | $-18.08M | $-27.15M | $-32.61M | $-29.65M | $-27.20M | $-33.47M | $-34.08M | $-35.49M | $-26.68M | $-34.65M | $-46.53M | $-54.47M | $-43.96M | $-42.59M | $-46.95M | $-24.00 | $-43.27M | $-47.13M |
| Low Forecast | $46.95M | $46.09M | $47.08M | $38.34M | $41.76M | $41.22M | $42.33M | $40.36M | $20.45M | $20.81M | $22.13M | $20.28M | $-20.44M | $-30.70M | $-36.88M | $-39.30M | $-34.32M | $-37.84M | $-38.53M | $-40.13M | $-30.62M | $-39.18M | $-52.61M | $-61.59M | $-49.71M | $-42.59M | $-46.95M | $-36.00 | $-43.27M | $-47.13M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.60% | 0.49% | 0.53% | 0.61% | 0.61% | 0.57% | 946400.00% | 0.66% | 0.64% |
UroGen Pharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. URGN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
UroGen Pharma SG&A Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $21.75M | $22.49M | $24.47M | $21.63M | $19.07M | $20.83M | $21.30M | $87.53M | $21.62M |
| Avg Forecast | $125.72B | $120.89B | $120.89B | $116.05B | $123.28B | $118.54B | $118.54B | $113.79B | $68.32B | $65.69B | $65.69B | $63.07B | $32.51B | $23.77B | $18.28B | $15.32B | $17.54B | $16.25B | $16.09B | $14.36B | $15.15B | $13.45B | $13.51B | $11.49B | $12.43B | $13.52B | $11.56B | $22.00 | $10.90B | $10.31B |
| High Forecast | $132.93B | $127.81B | $127.81B | $122.70B | $130.34B | $125.32B | $125.32B | $120.31B | $72.24B | $69.46B | $69.46B | $66.68B | $34.37B | $25.13B | $19.33B | $15.47B | $18.11B | $17.18B | $16.09B | $15.18B | $15.49B | $13.45B | $14.28B | $12.14B | $13.14B | $13.52B | $11.56B | $27.00 | $10.90B | $10.31B |
| Low Forecast | $120.91B | $116.26B | $116.26B | $111.61B | $118.56B | $114.00B | $114.00B | $109.44B | $65.71B | $63.18B | $63.18B | $60.65B | $31.27B | $22.86B | $17.58B | $15.17B | $16.97B | $15.63B | $16.09B | $13.81B | $14.81B | $13.45B | $12.99B | $11.05B | $11.95B | $13.52B | $11.56B | $18.00 | $10.90B | $10.31B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 968181.82% | 0.01% | 0.00% |
UroGen Pharma's average Quarter SG&A projection for Dec 23 is $15.15B, based on 3 Wall Street analysts, with a range of $14.81B to $15.49B. The forecast indicates a 69535.82% rise compared to URGN last annual SG&A of $21.75M (Sep 23).
UroGen Pharma EPS Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.68 | $-1.03 | $-1.30 | $-1.22 | $-1.13 | $-1.18 | $-1.25 | $-1.27 | $-1.35 |
| Avg Forecast | $1.15 | $1.13 | $1.15 | $0.94 | $1.02 | $1.01 | $1.03 | $0.99 | $0.50 | $0.51 | $0.54 | $0.50 | $-0.44 | $-0.66 | $-0.80 | $-0.80 | $-0.72 | $-0.82 | $-0.83 | $-0.87 | $-0.68 | $-0.85 | $-1.14 | $-1.33 | $-1.07 | $-1.16 | $-1.27 | $-1.33 | $-1.18 | $-1.28 |
| High Forecast | $1.23 | $1.21 | $1.24 | $1.01 | $1.10 | $1.08 | $1.11 | $1.06 | $0.54 | $0.55 | $0.58 | $0.53 | $-0.42 | $-0.63 | $-0.76 | $-0.69 | $-0.63 | $-0.78 | $-0.79 | $-0.82 | $-0.62 | $-0.80 | $-1.08 | $-1.26 | $-1.02 | $-1.16 | $-1.27 | $-1.33 | $-1.18 | $-1.28 |
| Low Forecast | $1.09 | $1.07 | $1.09 | $0.89 | $0.97 | $0.96 | $0.98 | $0.94 | $0.47 | $0.48 | $0.51 | $0.47 | $-0.47 | $-0.71 | $-0.86 | $-0.91 | $-0.80 | $-0.88 | $-0.89 | $-0.93 | $-0.71 | $-0.91 | $-1.22 | $-1.43 | $-1.15 | $-1.16 | $-1.27 | $-1.33 | $-1.18 | $-1.28 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.80% | 0.91% | 0.98% | 1.14% | 0.98% | 0.93% | 0.94% | 1.08% | 1.05% |
According to undefined Wall Street analysts, UroGen Pharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to URGN previous annual EPS of $NaN (undefined).
UroGen Pharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XLO | Xilio Therapeutics | $0.93 | $7.00 | 652.69% | Buy |
| PEPG | PepGen | $4.30 | $29.50 | 586.05% | Buy |
| VIGL | Vigil Neuroscience | $1.73 | $11.00 | 535.84% | Buy |
| CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
| CMPX | Compass Therapeutics | $1.53 | $5.00 | 226.80% | Buy |
| CELC | Celcuity | $12.55 | $39.00 | 210.76% | Buy |
| OVID | Ovid Therapeutics | $1.06 | $3.00 | 183.02% | Buy |
| PRTC | PureTech Health | $21.80 | $57.00 | 161.47% | Buy |
| ERAS | Erasca | $2.63 | $6.00 | 128.14% | Buy |
| URGN | UroGen Pharma | $11.33 | $25.00 | 120.65% | Buy |
| TYRA | Tyra Biosciences | $15.22 | $31.75 | 108.61% | Buy |
| ELVN | Enliven Therapeutics | $24.39 | $39.50 | 61.95% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| CNTB | Connect Biopharma | $1.06 | $1.50 | 41.51% | Buy |
| KRON | Kronos Bio | $0.96 | $1.00 | 4.17% | Buy |
| SRRK | Scholar Rock | $43.65 | $40.50 | -7.22% | Buy |
| IKNA | Ikena Oncology | $1.62 | $1.33 | -17.90% | Buy |